Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 May;59(5):1633–1638. doi: 10.1128/iai.59.5.1633-1638.1991

Gamma interferon suppresses acute and chronic Trypanosoma cruzi infection in cyclosporin-treated mice.

R McCabe 1, S Meagher 1, B Mullins 1
PMCID: PMC257895  PMID: 1902193

Abstract

To determine if exogenous gamma interferon is effective in immunosuppressed mice infected with Trypanosoma cruzi, recombinant murine gamma interferon was administered to cyclosporin-treated mice with either acute or chronic T. cruzi infection. Gamma interferon significantly decreased parasitemia and prevented death in acutely infected mice. Parasitemias and mortality of mice treated with both gamma interferon and cyclosporin were similar to those of immunocompetent controls. In chronically infected mice, cyclosporin treatment produced significantly more organ explant cultures positive for T. cruzi. Fewer positive cultures, particularly for spleen and heart, were obtained from cyclosporin-treated mice when they also received gamma interferon. Ketoconazole treatment of mice resulted in no positive cultures. Cyclosporin treatment did not prevent activation of peritoneal macrophages by parenteral gamma interferon, nor did it have a consistent effect on serum titers of alpha/beta or gamma interferon in response to a second challenge inoculum of T. cruzi. These data indicate that exogenous gamma interferon suppresses acute and chronic T. cruzi infection in cyclosporin-treated mice but that gamma interferon is not as effective as the relatively specific antimicrobial ketoconazole. Gamma interferon activates macrophages despite cyclosporin treatment, and its effects appear to be tissue specific.

Full text

PDF
1637

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRENER Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo. 1962 Nov-Dec;4:389–396. [PubMed] [Google Scholar]
  2. Badaro R., Falcoff E., Badaro F. S., Carvalho E. M., Pedral-Sampaio D., Barral A., Carvalho J. S., Barral-Netto M., Brandely M., Silva L. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med. 1990 Jan 4;322(1):16–21. doi: 10.1056/NEJM199001043220104. [DOI] [PubMed] [Google Scholar]
  3. Calne R. Y. Immunosuppression for organ grafting -- observations on cyclosporin A. Immunol Rev. 1979;46:113–124. doi: 10.1111/j.1600-065x.1979.tb00286.x. [DOI] [PubMed] [Google Scholar]
  4. Espevik T., Figari I. S., Shalaby M. R., Lackides G. A., Lewis G. D., Shepard H. M., Palladino M. A., Jr Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med. 1987 Aug 1;166(2):571–576. doi: 10.1084/jem.166.2.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Granelli-Piperno A., Andrus L., Steinman R. M. Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med. 1986 Apr 1;163(4):922–937. doi: 10.1084/jem.163.4.922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Green J. A., Yeh T. J., Overall J. C., Jr Rapid, quantitative, semiautomated assay for virus-induced and immune human interferons. J Clin Microbiol. 1980 Sep;12(3):433–438. doi: 10.1128/jcm.12.3.433-438.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Harms G., Zwingenberger K., Chéhadé A. K., Talhari S., Racz P., Mouakeh A., Douba M., Näkel L., Naiff R. D., Kremsner P. G. Effects of intradermal gamma-interferon in cutaneous leishmaniasis. Lancet. 1989 Jun 10;1(8650):1287–1292. doi: 10.1016/s0140-6736(89)92686-x. [DOI] [PubMed] [Google Scholar]
  8. Hoff R. Killing in vitro of Trypanosoma cruzi by macrophages from mice immunized with T. cruzi or BCG, and absence of cross-immunity on challege in vivo. J Exp Med. 1975 Aug 1;142(2):299–311. doi: 10.1084/jem.142.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kierszenbaum F., Gottlieb C. A., Budzko D. B. Exacerbation of Trypanosoma cruzi infection in mice treated with the immunoregulatory agent cyclosporin A. Tropenmed Parasitol. 1983 Mar;34(1):4–6. [PubMed] [Google Scholar]
  10. Kierszenbaum F., Sonnenfeld G. Characterization of the antiviral activity produced during Trypanosoma cruzi infection and protective effects of exogenous interferon against experimental Chagas' disease. J Parasitol. 1982 Apr;68(2):194–198. [PubMed] [Google Scholar]
  11. McCabe R. E., Luft B. J., Remington J. S. Effect of murine interferon gamma on murine toxoplasmosis. J Infect Dis. 1984 Dec;150(6):961–962. doi: 10.1093/infdis/150.6.961. [DOI] [PubMed] [Google Scholar]
  12. McCabe R. E., Meagher S., Mullins B. Trypanosoma cruzi: explant organ cultures from mice with chronic Chagas' disease. Exp Parasitol. 1989 May;68(4):462–469. doi: 10.1016/0014-4894(89)90131-8. [DOI] [PubMed] [Google Scholar]
  13. McCabe R. E., Mullins B. T. Failure of Trypanosoma cruzi to trigger the respiratory burst of activated macrophages. Mechanism for immune evasion and importance of oxygen-independent killing. J Immunol. 1990 Mar 15;144(6):2384–2388. [PubMed] [Google Scholar]
  14. McCabe R. E., Remington J. S., Araujo F. G. In vivo and in vitro effects of cyclosporin A on Trypanosoma cruzi. Am J Trop Med Hyg. 1985 Sep;34(5):861–865. doi: 10.4269/ajtmh.1985.34.861. [DOI] [PubMed] [Google Scholar]
  15. McCabe R. E., Remington J. S., Araujo F. G. Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. J Infect Dis. 1984 Oct;150(4):594–601. doi: 10.1093/infdis/150.4.594. [DOI] [PubMed] [Google Scholar]
  16. McCabe R. E., Remington J. S., Araujo F. G. Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. J Infect Dis. 1984 Oct;150(4):594–601. doi: 10.1093/infdis/150.4.594. [DOI] [PubMed] [Google Scholar]
  17. McCabe R. E., Remington J. S., Araujo F. G. Ketoconazole promotes parasitological cure of mice infected with Trypanosoma cruzi. Trans R Soc Trop Med Hyg. 1987;81(4):613–615. doi: 10.1016/0035-9203(87)90430-5. [DOI] [PubMed] [Google Scholar]
  18. McCabe R. Failure of ketoconazole to cure chronic murine Chagas' disease. J Infect Dis. 1988 Dec;158(6):1408–1409. doi: 10.1093/infdis/158.6.1408. [DOI] [PubMed] [Google Scholar]
  19. Melo R. C., Brener Z. Tissue tropism of different Trypanosoma cruzi strains. J Parasitol. 1978 Jun;64(3):475–482. [PubMed] [Google Scholar]
  20. Murphy P. M., Lane H. C., Gallin J. I., Fauci A. S. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma. Ann Intern Med. 1988 Jan;108(1):36–41. doi: 10.7326/0003-4819-108-1-36. [DOI] [PubMed] [Google Scholar]
  21. Murray H. W. Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis. J Infect Dis. 1990 May;161(5):992–994. doi: 10.1093/infdis/161.5.992. [DOI] [PubMed] [Google Scholar]
  22. Nakane A., Minagawa T., Yasuda I., Yu C., Kato K. Prevention by gamma interferon of fatal infection with Listeria monocytogenes in mice treated with cyclosporin A. Infect Immun. 1988 Aug;56(8):2011–2015. doi: 10.1128/iai.56.8.2011-2015.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nathan C. F., Horowitz C. R., de la Harpe J., Vadhan-Raj S., Sherwin S. A., Oettgen H. F., Krown S. E. Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8686–8690. doi: 10.1073/pnas.82.24.8686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Nathan C. F., Kaplan G., Levis W. R., Nusrat A., Witmer M. D., Sherwin S. A., Job C. K., Horowitz C. R., Steinman R. M., Cohn Z. A. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med. 1986 Jul 3;315(1):6–15. doi: 10.1056/NEJM198607033150102. [DOI] [PubMed] [Google Scholar]
  25. Neva F. A. Immunotherapy for parasitic disease. N Engl J Med. 1990 Jan 4;322(1):55–57. doi: 10.1056/NEJM199001043220111. [DOI] [PubMed] [Google Scholar]
  26. Pick E., Mizel D. Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader. J Immunol Methods. 1981;46(2):211–226. doi: 10.1016/0022-1759(81)90138-1. [DOI] [PubMed] [Google Scholar]
  27. Quan P. C., Rager-Zisman B., Wittner M., Tanowitz H. B. Interferon and natural killer cells in murine Chagas' disease. J Parasitol. 1983 Dec;69(6):1164–1166. [PubMed] [Google Scholar]
  28. Reed S. G. In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol. 1988 Jun 15;140(12):4342–4347. [PubMed] [Google Scholar]
  29. Rothermel C. D., Rubin B. Y., Murray H. W. Gamma-interferon is the factor in lymphokine that activates human macrophages to inhibit intracellular Chlamydia psittaci replication. J Immunol. 1983 Nov;131(5):2542–2544. [PubMed] [Google Scholar]
  30. Rytel M. W., Marsden P. D. Induction of an interferon-like inhibitor by Trypanosoma cruzi infection in mice. Am J Trop Med Hyg. 1970 Nov;19(6):929–931. doi: 10.4269/ajtmh.1970.19.929. [DOI] [PubMed] [Google Scholar]
  31. Shidani B., Milon G., Marchal G., Truffa-Bachi P. Cyclosporin A inhibits the delayed-type hypersensitivity reaction: impaired production of early pro-inflammatory mediator(s). Eur J Immunol. 1984 Apr;14(4):314–318. doi: 10.1002/eji.1830140407. [DOI] [PubMed] [Google Scholar]
  32. Sonnenfeld G., Kierszenbaum F. Increased serum levels of an interferon-like activity during the acute period of experimental infection with different strains of Trypanosoma cruzi. Am J Trop Med Hyg. 1981 Nov;30(6):1189–1191. doi: 10.4269/ajtmh.1981.30.1189. [DOI] [PubMed] [Google Scholar]
  33. Spitalny G. L., Havell E. A. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J Exp Med. 1984 May 1;159(5):1560–1565. doi: 10.1084/jem.159.5.1560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Thomson A. W., Webster L. M. The influence of cyclosporin A on cell-mediated immunity. Clin Exp Immunol. 1988 Mar;71(3):369–376. [PMC free article] [PubMed] [Google Scholar]
  35. Yeh T. J., McBride P. T., Overall J. C., Jr, Green J. A. Automated, quantitative cytopathic effect reduction assay for interferon. J Clin Microbiol. 1982 Aug;16(2):413–415. doi: 10.1128/jcm.16.2.413-415.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES